Biotechnology
Investing News
Market News
Gilead Reports Phase 3 Trial Results in Patients with Coronvirus
Gilead Sciences, Inc. (NASDAQ: GILD) reported topline results from its Phase 3 SIMPLE trials in patients with COVID-19 pneumonia. The study evaluated patients on 5-day and 10-day courses of...